Stock Region wrote a post · Mar 5, 2024 01:39

Investment Firm Raises Price Target For Major Biotech Company

Mizuho Boosts MiMedx Group's Price Target to $14, Continues Bullish Outlook.

In a recent move that underscores their confidence in the regenerative medicine sector, Mizuho Securities has maintained its 'Buy' rating on MiMedx Group Inc. (NASDAQ: MDXG) and has raised the price target from a previous estimate to $14. This comes as the company continues to make significant strides in its advanced wound care and surgical tissue solutions. $MiMedx (MDXG.US)$

https://stockregion.app/p/investment-firm-raises-price-target-dc7

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

5773 Views

Comment

Stock Region

252

Followers

Following

536

Visitors